NEW YORK (GenomeWeb News) – PrimeraDx has landed a grant from the National Cancer Institute to develop a gene expression profiling assay that can rapidly detect diffuse large B-Cell lymphoma (DLBCL) subgroups, making it easier to diagnose the disease, select treatment options, and predict the likelihood of patient response to therapy and survival.

The company will use the $335,186 grant, funded under the Innovative Molecular Analysis Technologies Program, to develop the assay on its ICEPlex PCR-based platform, which uses formalin-fixed, paraffin-embedded specimens.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.